welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
study id #: NCT01245816
condition: Familial Adenomatous Polyposis
status: withdrawn
purpose:The purpose of this phase III study is to evaluate the safety and efficacy of the combination of eflornithine and sulindac compared to single agent sulindac or eflornithine in reducing the number of polyps in patients with familial adenomatous polyposis (FAP).
intervention:
Drug: Eflornithine plus Sulindac
Drug: Eflornithine plus Placebo
Drug: Sulindac plus Placebo
expertly curated content related to this topic
-
Let’s Get Clinical: Health Advocacy + an F.A.P. Clinical Trialhttps://www.youtube.com/watch?v=LbeqxDfv...
-
Bonnies Diary Nov 07https://jtvcancersupport.com/embed/26653...
-
Thetis Pharmaceuticals Awarded Key Patent on HEALER TechnologyThetis Pharmaceuticals LLC, a privately-...
-
Surgical Treatment of Familial Adenomatous Polyposis: Ileorectal Anastomosis or Restorative Proctolectomy?CONTEXT : Controversy regarding the best...
-
Prostanoids, Ornithine Decarboxylase, and Polyamines in Primary Chemoprevention of Familial Adenomatous PolyposisBACKGROUND & AIMS : Familial adenoma...
-
Different Surgical Strategies in the Treatment of Familial Adenomatous Polyposis: What’s the Role of the Ileal...BACKGROUND AND STUDY AIMS: Restorative ...
-
Coping and relaxation techniques with medical procedureshttps://www.youtube.com/watch?v=_tUhIYzA...